Notis McConarty Edward purchased a new position in shares of Merck KGaA (OTCMKTS:MKGAF – Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 10,150 shares of the company’s stock, valued at approximately $1,304,000.
A number of other hedge funds also recently made changes to their positions in the stock. Frazier Financial Advisors LLC purchased a new stake in shares of Merck KGaA during the 2nd quarter valued at $25,000. Addison Advisors LLC acquired a new position in Merck KGaA in the second quarter valued at $90,000. Comprehensive Financial Planning Inc. PA acquired a new position in Merck KGaA in the second quarter valued at $134,000. Stevens Capital Partners purchased a new stake in Merck KGaA during the second quarter valued at about $220,000. Finally, United Bank purchased a new stake in Merck KGaA during the second quarter valued at about $248,000. Institutional investors and hedge funds own 0.10% of the company’s stock.
Merck KGaA Stock Performance
Shares of OTCMKTS:MKGAF opened at $167.38 on Thursday. The firm has a market capitalization of $21.63 billion, a PE ratio of 25.55 and a beta of 0.96. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.31 and a quick ratio of 0.84. The business has a 50-day moving average of $162.50 and a two-hundred day moving average of $148.28. Merck KGaA has a 12 month low of $116.68 and a 12 month high of $175.56.
Merck KGaA Company Profile
Merck KGaA, headquartered in Darmstadt, Germany, is a long-established multinational chemical and pharmaceutical company with roots dating back to 1668. Operating under the brand Merck Group (and using distinct consumer-facing names in certain regions to avoid confusion with other companies of similar name), the company is privately controlled by the Merck family and organizes its activities across multiple business units that serve customers in Europe, the Americas, Asia-Pacific and beyond.
The company’s operations are organized mainly into three businesses.
Featured Stories
- Five stocks we like better than Merck KGaA
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
- Is Apple’s AI Strategy Smarter Than Skeptics Think?
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.
